Nurix Therapeutics Inc
NRIX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.54B
Close$
Share Statistics
| Market cap | $1.54 Billion |
|---|---|
| Enterprise Value | $1.55 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.05 |
| Beta | 1.88 |
| Outstanding Shares | 110,071,668 |
Return
| Return on Equity | -61.40% |
|---|---|
| Return on Assets | -46.42% |
| Return on Invested Capital | -56.16% |
Valuation & Multiples
| P/E Ratio | -6.62 |
|---|---|
| PEG | -12.1 |
| Price to Sales | - |
| Price to Book Ratio | 3.87 |
| Enterprise Value to Revenue | 21.53 |
| Enterprise Value to EBIT | -5.06 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 14, 2026
EPS Estimate
$-0.76
Average shareholder expectationRevenue Estimate
$14.25 M
Average shareholder expectationNext Earnings Call
Expected Date
July 8, 2026
EPS Estimate
$-0.74
Average shareholder expectationRevenue Estimate
$15.92 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0575▼ 29.96% |
|---|---|
| Total Calls | 250,600▲ 7.28% |
| Total Puts | 14,400▼ 82.73% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 106.32%▼ 24.55% |
|---|---|
| Total Invested | $1.81B▼ 15.69% |
| Investors Holding | 197▲ 11.00% |
ESG Score
No data
About Nurix Therapeutics Inc
2,020 employeesNurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other ch...